These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
325 related items for PubMed ID: 16782732
1. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Flendrie M, Creemers MC, van Riel PL. Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732 [Abstract] [Full Text] [Related]
2. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH. Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109 [Abstract] [Full Text] [Related]
3. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306 [Abstract] [Full Text] [Related]
4. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L. Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995 [Abstract] [Full Text] [Related]
5. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F. Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989 [Abstract] [Full Text] [Related]
6. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T. Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148 [Abstract] [Full Text] [Related]
7. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J. Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624 [Abstract] [Full Text] [Related]
8. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D. Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078 [Abstract] [Full Text] [Related]
9. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P. Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046 [Abstract] [Full Text] [Related]
10. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P. Arthritis Rheum; 2007 Apr 15; 57(3):448-53. PubMed ID: 17394231 [Abstract] [Full Text] [Related]
11. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial. J Rheumatol; 2002 Apr 15; 29(4):667-77. PubMed ID: 11950005 [Abstract] [Full Text] [Related]
15. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP. Ann Rheum Dis; 2008 Apr 15; 67(4):563-6. PubMed ID: 18042642 [Abstract] [Full Text] [Related]
19. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Arthritis Res Ther; 2005 Jul 15; 7(5):R1063-71. PubMed ID: 16207323 [Abstract] [Full Text] [Related]
20. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Thurlings RM, Vos K, Gerlag DM, Tak PP. Arthritis Rheum; 2008 Dec 15; 58(12):3657-64. PubMed ID: 19035505 [Abstract] [Full Text] [Related] Page: [Next] [New Search]